Ownership and insider activity for Repligen Corporation (RGEN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing.
Price
| Price | $189.50 |
| Market Cap | $10.7B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-02 | Loeillot Olivier | F-InKind | 1,248 | $227K |
| 2026-09-25 | Garland Jason K | F-InKind | 421 | $80K |
| 2026-09-24 | Loeillot Olivier | M-Exempt | 8,404 | $1.3M |
| 2026-09-24 | Loeillot Olivier | M-Exempt | 4,542 | $706K |
| 2026-09-24 | Loeillot Olivier | S-Sale | 4,542 | $863K |
| 2026-09-24 | Loeillot Olivier | M-Exempt | 8,404 | $1.3M |
| 2026-09-24 | Loeillot Olivier | M-Exempt | 4,542 | $706K |
| 2026-09-21 | Loeillot Olivier | M-Exempt | 5,426 | $769K |
| 2026-09-21 | Loeillot Olivier | S-Sale | 5,426 | $977K |
| 2026-09-21 | Loeillot Olivier | M-Exempt | 5,426 | $769K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $141.8M | $173.8M | $193.8M | $528.4M | $717.3M | $603.8M | $523.5M | $751.3M | $757.4M | $566.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | $100.3M | 0 | 0 | $201.6M |
| Receivables | $16.0M | $27.7M | $35.8M | $43.7M | $71.4M | $117.4M | $116.2M | $124.2M | $134.1M | $158.6M |
| Inventory | $24.7M | $39.0M | $42.3M | $54.8M | $95.0M | $184.5M | $238.3M | $202.3M | $143.0M | $170.5M |
| Total Current Assets | $184.2M | $242.8M | $275.7M | $641.8M | $902.4M | $931.7M | $998.1M | $1.11B | $1.07B | $1.14B |
| Property, Plant & Equipment | $15.0M | $22.4M | $32.2M | $74.2M | $92.0M | $226.5M | $315.7M | $323.0M | $333.1M | $306.2M |
| Goodwill | $59.5M | $327.3M | $326.7M | $468.4M | $618.3M | $860.4M | $855.5M | $987.1M | $1.03B | $1.11B |
| Intangible Assets | $29.8M | $144.8M | $135.4M | $212.6M | $287.1M | $337.3M | $360.6M | $407.0M | $397.9M | $386.1M |
| Total Assets | $288.9M | $120.4M | $139.4M | $1.40B | $1.90B | $2.36B | $2.53B | $2.83B | $2.83B | $2.95B |
| Accounts Payable | $5.1M | $7.3M | $10.5M | $11.4M | $16.9M | $36.2M | $27.6M | $19.6M | $32.1M | $30.0M |
| Short-term Debt | 0 | 0 | $103.5M | 0 | $243.7M | $255.3M | $284.6M | $69.5M | 0 | $21.6M |
| Total Current Liabilities | $21.1M | $25.2M | $129.8M | $48.3M | $319.0M | $375.3M | $404.2M | $164.9M | $126.8M | $135.8M |
| Long-term Debt | $95.3M | $99.2M | 0 | $232.8M | 0 | 0 | 0 | $510.1M | $525.6M | $542.2M |
| Total Liabilities | $120.1M | $152.0M | $159.1M | $340.3M | $373.7M | $608.3M | $620.9M | $866.3M | $856.9M | $843.6M |
| Retained Earnings | -$59.9M | -$31.5M | -$15.6M | $5.8M | $65.8M | $194.1M | $397.3M | $432.9M | $407.4M | $456.2M |
| Total Equity | $168.8M | $591.5M | $615.6M | $1.06B | $1.53B | $1.75B | $1.91B | $1.96B | $1.97B | $2.11B |
| Total Debt | $95.3M | $99.2M | $103.5M | $263.3M | $275.4M | $366.1M | $423.0M | $711.8M | $686.2M | $689.9M |
| Net Debt | -$46.5M | -$74.5M | -$90.3M | -$265.1M | -$441.9M | -$237.8M | -$200.8M | -$39.5M | -$71.1M | -$77.7M |
| Working Capital | $163.1M | $217.6M | $145.9M | $593.5M | $583.4M | $556.4M | $593.9M | $946.4M | $939.3M | $1.00B |
Financial Health
| Debt / Equity | 0.33 |
| Current Ratio | 9.05 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 7.49 |
Profitability
| Return on Equity | 1.98% |
| Return on Invested Capital | 1.83% |
| Return on Assets | 1.41% |
| Gross Margin | 51.05% |
| Operating Margin | 8.32% |
| Net Margin | 5.29% |
Related companies: ATR · AVTR · BAX · BIO · CRL · DVA · GMED
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of RGEN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks